In vivo effects of remoxipride and aromatic ring metabolites in the rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1356-1366

  Ahlenius, Sven ^a   Ericson, Evalena ^a   Hillegaart, Viveka ^a   Nilsson, Lars B ^a   Salmi, Peter ^a   Wijkström, Agneta ^a  

^a Astra Arcus AB ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 5 HYDROXY 2,6 DIMETHOXYBENZAMIDE; 3 BROMO N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 6 METHOXYSALICYLAMIDE; 5 HYDROXYTRYPTOPHAN; DOPA; FLA 908; REMOXIPRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; DEXTROAMPHETAMINE; DIHYDROXYPHENYLALANINE; MALE; MOTOR ACTIVITY; PROSENCEPHALON; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; REMOXIPRIDE; SALICYLAMIDES; SEROTONIN;

EID: 0031460386     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. 1A agonist 8-OH-DPAT in the rat. Pharmacol. Toxicol. 64: 3-5, 1989.
2. AHLENIUS, S., BRIEM, S., HILLEGAART, V. AND MAGNUSSON, O.: Diffusion and absorption of (-)sulpiride and raclopride after intracerebral administration in the rat. Biochem. Pharmacol. 39: 2066-2069, 1990.
3. AHLENUIS, S., ERICSON, E., HÖGBERG, K. AND WIJKSTRÖM, A.: Behavioural and biochemical effects of subchronic treatment with raclopride in the rat: Tolerance and brain monoamine receptor sensitivity. Pharmacol. Toxicol. 68: 302-309, 1991.
4. AHLENIUS, S., ERICSON, E. AND WIJKSTRÖM, A.: Stimulation of brain dopamine autoreceptors by remoxipride administration in reserpine-treated male rats. J. Pharm. Pharmacol. 45: 237-239, 1993.
5. AHLENIUS, S. AND HILLEGAART, V.: Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: A comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol. Biochem. Behav. 24: 1409-1415, 1986.
6. 2 antagonist and prolactin response in acute schizophrenia: Results from remoxipride studies. The Canadian Remoxipride Study Group. Progr. Neuropsychopharmacol. Biol. Psychiatry 14: 769-777, 1990.
7. CARLSSON, A., DAVIS, J. N., KEHR, W., LINDQVIST, M. AND ATACK, C. V.: Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg's Arch. Pharmacol. 275: 153-168, 1972.
8. CHOUINARD, G.: Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J. Clin. Psychopharmacol. 7: 159-164, 1987.
9. 2 receptor agonists in the treatment of schizophrenia. Psychopharmacol. Bull. 25: 393-397, 1989.
10. DEN BOER, J. A. AND WESTENBERG, H. G. M.: Atypical neuroleptics in acute schizophrenia: A double-blind comparative study of remoxipride and haloperidol. Psychopharmacol. Bull. 26: 99-107, 1990.
11. DRAPER, N. R. AND SMITH, H.: Applied Regression Analysis, pp.1-43, Wiley, New York, 1966.
12. ERICSON, E., SAMUELSSON, J. AND AHLENIUS, S.: Photocell measurements of rat motor activity: A contribution to sensitivity and variation in behavioral observations. J. Pharmacol. Methods 25: 111-122, 1991.
13. FLORVALL, L. AND ÖGREN, S.-O.: Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities. J. Med. Chem. 25: 1280-1286, 1982.
14. GAWELL, L., HAGBERG, C.-E., HÖGBERG, T. AND WIDMAN, M.: Synthesis of 5-substituted 5-hydroxy-2-pyrrolidones, metabolites of the antipsychotic benzamide remoxipride. Acta Chem. Scand. 43: 476-480, 1989.
15. HALL, H., SÄLLEMARK, M. AND JERNING, E.: Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Pharmacol. Toxicol. 58: 61-70, 1986.
16. HJORTH, S., CARLSSON, A., CLARK, D., SVENSSON, K., WIKSTRÖM, H., SANCHEZ, D., LINDBERG, P., HACKSELL, U., ARVIDSSON, L.-E., JOHANSSON, A. AND NILSSON, J. L. G.: Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology 81: 89-99, 1983.
17. 2 antagonists as antipsychotic agents. Pharmacological, chemical, structural and theoretical considerations. Acta Pharm. Suec. 24: 289-328, 1987.
18. JACKSON, D. M., MOHELL, N., BENGTSSON, A. AND MALMBERG, Å.: What are atypical neuroleptics and how do they work? In New Generation of Antipsychotic Drugs: Novel Mechanisms of Action, ed. by N. Brunello, J. Mendlewicz and G. Racagni, pp. 27-38, Karger, Basel, 1993.
19. KEKS, N., MCGRATH, J., LAMBERT, T., CATTS, S., VADDADI, K., BURROWS, G., VAHGHESE, F., GEORGE, T., HUSTIG, H., BURNETT, P., KERR, K., ZORBAS, A., HILL, C., STEDMAN, T., JOHNSON, G., LEIBERT, B., COPOLOV, D., MACKENZIE, M. AND DILLENBECK, C.: The Australian multicentre double blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psvchiatr. Scand. 90: 358-365, 1994.
20. KEPPEL, G.: Design and Analysis: A Researcher's Handbook, Prentice Hall, Englewood Cliffs, 1973.
21. KLIESER, E., STRAUSS, W. H. AND LEMMER, W.: The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psychiatr. Scand. Suppl. 380: 68-73, 1994.
22. 2 receptors in the rat brain. Biochem. Pharmacol. 34: 2251-2259, 1985.
23. LAHDELMA, R. L., APPELBERG, B., KUOPPASALMI, K., RATILA, H. AND RIMON, R.: Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients. Eur. Neuropsychopharmacol. 1: 535-540, 1991.
24. 2 antagonists. Human Psychopharmacol. 10: 455-460, 1995.
25. LARGENT, B. L., WIKSTRÖM, H., SNOWMAN, A. M. AND SNYDER, S. H.: Novel antipsychotic drugs share high affinity for sigma receptors. Eur. J. Pharmacol. 155: 345-347, 1988.
26. LEWANDER, T., WESTERBERGH, S.-E. AND MORRISON, D.: Clinical profile of remoxipride: A combined analysis of a comparative double-blind multicentre trial program. Acta Psychiatr. Scand. Suppl. 82: 92-98, 1990.
27. Li, C. C.: Introduction to Experimental Statistics, pp. 207-226, McGraw-Hill, New York, 1964.
28. 5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 281: 597-603, 1997.
29. 2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 25: 187-197, 1986.
30. MAGNUSSON, O., FOWLER, C. J., MOHRINGE, B., WIJKSTRÖM, A. AND OGREN, S.-O.: Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 337: 379-384, 1988.
31. 2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilization. J. Neural Transm. 69: 163-177, 1987a.
32. 2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration. Pharmacol. Toxicol. 60: 368-373, 1987b.
33. MAGNUSSON, O., NILSSON, L. B. AND WESTERLUND, D.: Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography-electrochemical detection system. J. Chromatogr. 221: 237-247, 1980.
34. 3 receptors. Mol. Pharmacol. 43: 749-754, 1993.
35. 3 receptors. Eur. J. Pharmacol. 238: 121-125. 1993.
36. MOHRINGE, B., MAGNUSSON, O., THORELL, G. AND FOWLER, C. J.: Seasonal variations in the stability of monoamines and their metabolites in perchloric acid as measured by high-performance liquid chromatography. J. Chromatogr. 361: 291-299, 1986.
37. NABER, D., GAUSSARES, C., MOEGLEN, J. M., TREMMEL, L. AND BAILEY, P. E.: The SDZ HDC 912 Collaborative Study Group. Efficacy and tolerability of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia. In Novel Antipsychotic Drugs, ed. by H. Y. Meltzer, pp. 99-107, Raven Press, New York, 1992.
38. NILSSON, C. L. AND ERIKSSON, E.: Effects of remoxipride and raclopride on prolactin release from clonal pituitary tumor cells. Pharmacol. Toxicol. 76: 85-88, 1995.
39. NILSSON, L. B.: Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. J. Chromatogr. 526: 139-150, 1990.
40. NILSSON, L. B.: High sensitivity determination of the remoxipride metabolite NCQ-344 in plasma by coupled column reversed phase liquid chromatography and electrochemical detection. Biomed. Chromatogr. 1997.
41. NISHIBE, Y., MATSUO, Y., YOSHIZAKI, T., EIGYO, M., SHIOMI, T. AND HIROSE, K.: Differential effects of sulpiride and metoclopramide on brain homovanillic acid levels and shuttle box avoidance after systemic and intracerebral administration. Naunyn-Schmiedeberg's Arch. Pharmacol. 321: 190-194, 1982.
42. 2 receptors and receptor functions in the rat. Pharmacol. Toxicol. 73: 325-334, 1993.
43. ÖGREN, S.-O., HALL, H., KÖHLER, C., MAGNUSSON, O., LINDBOM, L.-O., ANGEBY, K. AND FLORVALL, L.: Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur. J. Pharmacol. 102: 459-474, 1984.
44. 2 receptors. Neuroscience 61: 269-283, 1994.
45. 1 receptors in schizophrenia revealed by PET. Nature 385: 634-636, 1997.
46. PAXINOS, G. AND WATSON, C.: The Rat Brain in Stereotaxic Coordinates, Academic Press, London, 1986.
47. 1 receptor agonist. Eur. J. Pharmacol. 307: 27-31, 1996.
48. SALMI, P., KARLSSON, T. AND AHLENIUS, S.: Antagonism by SCH-23,390 of clozapine-induced hypothermia in the rat. Eur. J. Pharmacol. 253: 67-73, 1994.
49. SIEGEL, S.: Nonparametric Statistics for the Behavioral Sciences, McGraw-Hill, New York, 1956
50. SPANO, P. F., TRABUCCHI, M., CORSINI, G. U. AND GESSA, G. L.: Sulpiride and Other Benzamides, pp.1-312, Italian Brain Research Foundation Press, Milan, 1978.
51. TRABUCCHI, M., LONGONI, R., FRESIA, P. AND SPANO, P. F.: Sulpiride: A study of the effects on dopamine receptors in rat neostriatum and limbic forebrain. Life Sci. 17: 1551-1556, 1975.
52. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45-50, 1989.
53. VON BAHR, C., WIESEL, F.-. A., MOVIN, G., ENEROTH, P., JANSSON, P., NILSSON, L. AND OGENSTAD, S.: Neuroendocrine responses to single oral doses of remo-xipride and sulpiride in healthy female and male volunteers. Psychopharmacology 103: 443-448, 1991.
54. WADENBERG, M.-L.: Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev. 20: 325-339, 1996.
55. WADENBERG, M.-L. AND AHLENIUS, S.: Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy. J. Neural Transm. [GenSect] 83: 43-53, 1991.
56. WESTLIND-DANIELSSON, A., GUSTAFSSON, K. AND ANDERSSON, I.: Remoxipride shows low propensity to block functional striatal dopamine receptors in vitro. Eur. J. Pharmacol. 288: 89-95, 1994.
57. WIDMAN, M., NILSSON, L. B., BRYSKE, B., LUNDSTRÖM, J.: Disposition of remoxipride in different species: Species differences in metabolism. Arzneim.-Forsch. 43: 287-297, 1993.
58. WINER, B. J.: Statistical Principles in Experimental Design, McGraw-Hill, New York, 1971